What clinical, laboratory, and imaging criteria define a Crohn's disease flare?

Criteria for Crohn's Disease Flare-Up

A Crohn's disease flare is defined by the presence of active inflammation demonstrated through a combination of clinical symptoms (abdominal pain, increased stool frequency), elevated inflammatory biomarkers (CRP, fecal calprotectin >50 μg/g), and objective evidence of mucosal or transmural inflammation on endoscopy or cross-sectional imaging. 1, 2, 3, 4

Clinical Criteria

Active disease manifests with:

• ≥10 loose stools per day in severe flares
• Daily abdominal pain
• Anorectal symptoms (pain, urgency, incontinence, discharge, tenesmus)
• Systemic symptoms (fever, weight loss)
• CDAI score ≥220 defines moderate-to-severe disease (>450 indicates severe disease) 5

Important caveat: Clinical symptoms alone are unreliable—active inflammation can exist despite symptom resolution, and conversely, symptoms may occur without active inflammation 1, 6. This is why objective measures are essential.

Laboratory Criteria

Serum Markers

• Elevated C-reactive protein (CRP) - indicates systemic inflammation
• Low albumin - suggests severe disease
• Anemia - marker of chronic inflammation
• Neutrophil-to-lymphocyte ratio (NLR) - NLR shows strong correlation with moderate-to-severe activity 7

Fecal Markers

• Fecal calprotectin ≥50 μg/g has 87% sensitivity and 92% specificity for detecting active IBD 4
• Optimal cutoff of 43 μg/g demonstrated AUC of 0.871 for disease activity 8
• Calprotecin correlates better with colonic disease than isolated small bowel disease 3

Endoscopic Criteria

Colonoscopy with ileoscopy remains the gold standard for assessing mucosal inflammation 6, 4:

Active Disease Features:

• Deep ulcerations - correlate with severe inflammation and increased colectomy risk 2, 6
• Aphthous ulcers
• Cobblestone appearance
• Skip lesions with rectal sparing
• Longitudinal ulcers

Loss of endoscopic healing (Simple Endoscopic Score for Crohn's Disease ≥3 or presence of ulcerations) indicates active flare 3.

Imaging Criteria

CT/MR Enterography Findings 2, 9

Required features for active inflammation:

• Segmental mural hyperenhancement with wall thickening ≥5mm (moderate: 5-9mm; severe: ≥10mm)
• Asymmetric wall involvement (mesenteric border more affected) - specific for Crohn's disease
• Intramural edema on T2-weighted MRI (hyperintense signal on fat-saturated sequences)
• Restricted diffusion on DWI-MRI correlates with moderate-to-severe endoscopic inflammation

Markers of severe inflammation:

• Ulcerations visible on cross-sectional imaging (high-level evidence for severe disease) 2, 9
• Perienteric fat stranding
• Mesenteric hypervascularity
• Enlarged mesenteric lymph nodes

Venous phase ΔCT values and NLR are the strongest predictors of moderately active disease 7.

Intestinal Ultrasound

• Bowel wall thickness >3mm with increased vascularity on color Doppler
• Diagnostic accuracy approaches 95% for established CD (except rectum) 4
• Sensitivity 95%, specificity 77%, AUC 0.94 for detecting active disease 4

Complications Indicating Severe Flare

Penetrating disease:

• Fistulas, sinus tracts
• Intra-abdominal abscesses
• Free perforation

Stricturing disease:

• Luminal narrowing with upstream dilation >3cm (mild), >4cm (moderate-to-severe)
• Small bowel obstruction 2, 9

Algorithmic Approach to Assessment

1. Initial evaluation: Symptoms + fecal calprotectin

   • If calprotectin >50 μg/g → proceed to objective assessment

2. Objective confirmation:

   • Colonic/distal ileal disease: Ileocolonoscopy (highest sensitivity and accuracy) 8
   • Small bowel disease: MR enterography (preferred in patients <35 years, for monitoring, perianal disease) or CT enterography (preferred if >35 years, acute presentation, suspected abscess) 2

3. Severity grading: Combine endoscopic/imaging findings with biomarkers

   • Deep ulcers + CRP elevation + calprotectin >250 μg/g = severe flare
   • Wall thickening 5-9mm + moderate symptoms = moderate flare

Critical pitfall: Never rely on clinical symptoms alone to define a flare—up to 40% of patients in clinical remission have ongoing mucosal inflammation 1. Conversely, symptoms may be due to strictures, bacterial overgrowth, or IBS-like features rather than active inflammation.

The combination of CTE imaging features (venous phase ΔCT, wall thickness) with serological markers (NLR, PLR, CAR) achieves AUC of 0.947 for detecting active disease 7, superior to any single modality.